New combo therapy shows promise for untreatable liver cancer in large real-world study
NCT ID NCT07204327
First seen Oct 31, 2025 · Last updated May 22, 2026 · Updated 27 times
Summary
This study is checking how well a drug combination (atezolizumab plus bevacizumab) works when added to local treatments like chemoembolization or radiation for people with advanced liver cancer that can't be removed by surgery. About 1,136 patients from hospitals in China and the Asia-Pacific region are included. The main goal is to see if the combination helps people live longer, and the study also tracks side effects and how long the treatment keeps the cancer under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Zhongda Hospital, Southeast University
Nanjing, Jiangsu, 210009, China
Conditions
Explore the condition pages connected to this study.